Canada The government of the French-speaking Canadian province of Québec stands out for undertaking healthcare reforms while appreciating the need to join hands with industry when it comes to the promotion of health innovation. “Quebec has the most aggressive approach of any province in this country [for generics pricing]” Dr. Gaétan…

Generics With cost-cutting measures exacerbating an already fraught regulatory process, the Canadian generics industry is facing somewhat of an existential crisis. However, within this difficult market environment, enterprising generics companies are still seeing significant opportunities for growth. “Sometimes it seems as if [non-industry members] believe generic products grow on trees” Jim…

Colombia With the onset of universal public healthcare, new types of foreign actors have been spying fresh opportunities to penetrate the Colombian market. Inward investment from India, in particular, has been increasing year on year, while the number of government sponsored trade delegations promoting the import of India-manufactured generics has multiplied.…

Colombia With Latin America’s best healthcare system in terms of both coverage and quality, Colombia is fast becoming a destination of choice for multinationals, not only to set up shop in the sense of establishing a direct local affiliate, but also for opening regional headquarters and implanting managerial functions. “We are…

USA In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has approved 26 drugs; double the amount of the mid-year average since 2007. “The eight oncology treatments approved by the FDA this year represent…

Mexico According to a recent World Health Organization study, countries must allocate at least six percent of their GDP to research and development to be considered to have a healthy investment in this area. As Mexico currently only invests 1.8 percent of its GDP into R&D, there is clearly still a…

Mexico Mexico’s medical device segment displays promising growth indicators, with innovative companies providing integrated and digital solutions now firmly embedded within the healthcare landscape. However, regulatory obstacles as well as a lack of joined-up thinking in the public sector remain in place; potentially restricting the industry from realising its full potential.…

Mexico Representatives of Olivares, one of the leading law firms in Mexico, explain the evolving status of cannabis and narcotics for medicinal use in the country. A new Bill authorizing the use of cannabis for medical treatments was passed by the Senate in December 2016, but there is still a long…

USA While pledging to lower drug prices has proved popular, the Trump administration’s proposed FDA reform has been getting some pharmaceutical executives worried. In a meeting with Big Pharma CEOs at the end of January; US President Donald Trump called for drug prices to be lowered, US production of medicines to…

USA Take our poll on Donald Trump and Pharma at the bottom of the article Speaking at a White House meeting with senior pharmaceutical executives, US President Donald Trump told drug companies to lower their “astronomical” prices. He pledged to curb regulations and lower tax rates to allow companies to do so,…

Mexico Due to economic necessity, the Mexican government is attempting to slash annual spending; an act that could have serious consequences on the country’s ability to provide its citizens with healthcare. Here, representatives of government, associations, social security institutions, and private companies impart their expertise on how best to navigate these…

Pharma The Mexican pharmaceutical market’s capacity to change dramatically in a short period of time means that both innovators and generics companies must think strategically and “play their cards right” in order to succeed. From 2014 to 2015, the total Mexican pharmaceutical market displayed a strong 5.3 percent growth to reach…